{"id":"sirolimus-oral-product","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Hyperlipidemia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-25","effect":"Anemia"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Mouth ulcers/stomatitis"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL263427","moleculeType":"Small molecule","molecularWeight":"1189.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus binds to FKBP12 and subsequently inhibits mTOR complex 1 (mTORC1), which suppresses cell cycle progression and reduces T-cell and B-cell proliferation. This mechanism makes it useful as an immunosuppressant in transplantation and as an anti-proliferative agent in certain disease states, particularly those involving abnormal cell growth or immune dysregulation.","oneSentence":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key regulator of cell proliferation and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:17.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis"},{"name":"Lymphangioleiomyomatosis (LAM)"},{"name":"Tuberous sclerosis complex-associated conditions"}]},"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT02520063","phase":"PHASE1, PHASE2","title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-02-01","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT05237687","phase":"PHASE2","title":"The Role of Sirolimus in Preventing Functional Decline in Older Adults","status":"RECRUITING","sponsor":"Irina Timofte","startDate":"2026-02","conditions":"Aging","enrollment":10},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT01217931","phase":"PHASE2","title":"Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-19","conditions":"Kidney Cancer","enrollment":180},{"nctId":"NCT07369505","phase":"PHASE1","title":"Sapu003 in Advanced mTOR-sensitive Solid Tumors","status":"RECRUITING","sponsor":"SAPU NANO (US) LLC","startDate":"2025-12-15","conditions":"Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT05327023","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hematologic Neoplasms","enrollment":430},{"nctId":"NCT05104983","phase":"PHASE2","title":"Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study","status":"RECRUITING","sponsor":"Darcy Krueger","startDate":"2021-10-13","conditions":"Tuberous Sclerosis Complex, Epilepsy","enrollment":64},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT07095933","phase":"EARLY_PHASE1","title":"The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03-01","conditions":"Epilepsy, Drug Resistant","enrollment":5},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT04128722","phase":"PHASE2","title":"TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2020-02-14","conditions":"Lingual Microcystic Lymphatic Malformations","enrollment":12},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT04582136","phase":"PHASE3","title":"Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2021-03-04","conditions":"Systemic Lupus Erythematosus","enrollment":146},{"nctId":"NCT07058974","phase":"PHASE1","title":"A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-08-25","conditions":"Smokers, Former Smokers","enrollment":22},{"nctId":"NCT06341998","phase":"PHASE2, PHASE3","title":"Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children","status":"COMPLETED","sponsor":"Shandong First Medical University","startDate":"2020-06-01","conditions":"Germ Cell Tumor, Yolk Sac Tumor","enrollment":32},{"nctId":"NCT07165886","phase":"PHASE2, PHASE3","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-29","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":243},{"nctId":"NCT01734512","phase":"PHASE2","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12-13","conditions":"Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas","enrollment":65},{"nctId":"NCT04629495","phase":"PHASE2","title":"Rapamycin - Effects on Alzheimer's and Cognitive Health","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-08-11","conditions":"Mild Cognitive Impairment, Alzheimer Disease","enrollment":40},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT02517918","phase":"PHASE1","title":"Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2015-02","conditions":"Solid Tumor, Osteosarcoma","enrollment":23},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT04375813","phase":"PHASE2","title":"Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention","status":"RECRUITING","sponsor":"Robert Svatek","startDate":"2021-01-25","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":166},{"nctId":"NCT02246127","phase":"PHASE3","title":"Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2014-10-27","conditions":"Neuroendocrine Tumors","enrollment":141},{"nctId":"NCT06957379","phase":"PHASE2","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-29","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT05414292","phase":"NA","title":"Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2021-08-06","conditions":"Muscle Atrophy, Age-Related Sarcopenia","enrollment":16},{"nctId":"NCT02584647","phase":"PHASE1, PHASE2","title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","status":"TERMINATED","sponsor":"Gulam Manji","startDate":"2015-11-04","conditions":"Sarcoma, Malignant Peripheral Nerve Sheath Tumors","enrollment":39},{"nctId":"NCT06126588","phase":"PHASE2","title":"Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-29","conditions":"Meningioma","enrollment":28},{"nctId":"NCT05269849","phase":"PHASE2","title":"Sirolimus for Nosebleeds in HHT","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2022-03-16","conditions":"Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis","enrollment":10},{"nctId":"NCT02531932","phase":"PHASE2","title":"Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Amy Tiersten","startDate":"2015-12-16","conditions":"Breast Cancer","enrollment":64},{"nctId":"NCT02991807","phase":"PHASE1, PHASE2","title":"RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-06-12","conditions":"PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome","enrollment":46},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT06719791","phase":"EARLY_PHASE1","title":"Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-12-23","conditions":"Epilepsy, Drug Resistant","enrollment":15},{"nctId":"NCT06091332","phase":"PHASE2","title":"Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-01-05","conditions":"Cavernous Malformations, Intracerebral Hemorrhage, Brainstem Stroke","enrollment":75},{"nctId":"NCT06563817","phase":"PHASE2","title":"The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-08","conditions":"Communicating Hydrocephalus, Cerebral Intraventricular Hemorrhage, Secondary Normal Pressure Hydrocephalus","enrollment":53},{"nctId":"NCT05833815","phase":"PHASE2, PHASE3","title":"Addition of Everolimus to Standard of Care in Carcinoma Gallbladder","status":"RECRUITING","sponsor":"Banaras Hindu University","startDate":"2022-11-01","conditions":"Gallbladder Cancer","enrollment":56},{"nctId":"NCT03154281","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast","status":"COMPLETED","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2017-07-26","conditions":"Breast Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT04595513","phase":"PHASE1, PHASE2","title":"Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2020-09-08","conditions":"Tuberous Sclerosis Complex, Epilepsy","enrollment":5},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT05065411","phase":"PHASE3","title":"Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2022-04-11","conditions":"Metastatic Breast Cancer","enrollment":5},{"nctId":"NCT04987463","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants","status":"RECRUITING","sponsor":"Katarzyna Kotulska","startDate":"2021-05-07","conditions":"Tuberous Sclerosis Complex","enrollment":60},{"nctId":"NCT06160739","phase":"","title":"Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-11-20","conditions":"Microcystic Lymphatic Malformation, Combined Vascular Malformation, Vascular Malformations","enrollment":10},{"nctId":"NCT03901001","phase":"PHASE3","title":"Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-08","conditions":"Influenza","enrollment":160},{"nctId":"NCT01280669","phase":"PHASE2","title":"Intravitreal Sirolimus as Therapeutic Approach to Uveitis","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2022-09","conditions":"Uveitis, Intermediate Uveitis, Posterior Uveitis","enrollment":""},{"nctId":"NCT00934895","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2009-07-15","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT05534672","phase":"PHASE3","title":"Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex","status":"RECRUITING","sponsor":"Katarzyna Kotulska","startDate":"2023-01-23","conditions":"Tuberous Sclerosis Complex","enrollment":200},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT02106507","phase":"PHASE1","title":"ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-04","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT03696355","phase":"PHASE1","title":"Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-11-19","conditions":"Brain and Central Nervous System Tumors","enrollment":27},{"nctId":"NCT02071862","phase":"PHASE1","title":"Study of the Glutaminase Inhibitor CB-839 in Solid Tumors","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2014-02","conditions":"Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer","enrollment":210},{"nctId":"NCT05240781","phase":"NA","title":"Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-09-29","conditions":"High Bleeding Risk, Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":280},{"nctId":"NCT01499160","phase":"PHASE2","title":"Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis","enrollment":7},{"nctId":"NCT05190627","phase":"PHASE2","title":"Effect of Loratadine in Lymphangioleiomyomatosis","status":"UNKNOWN","sponsor":"Institut d'Investigació Biomèdica de Bellvitge","startDate":"2021-11-01","conditions":"Lymphangioleiomyomatosis","enrollment":62},{"nctId":"NCT02724020","phase":"PHASE2","title":"MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2016-06-30","conditions":"Clear-cell Metastatic Renal Cell Carcinoma","enrollment":96},{"nctId":"NCT00972335","phase":"PHASE2","title":"Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-01","conditions":"Intracranial Meningioma","enrollment":18},{"nctId":"NCT03047980","phase":"PHASE2, PHASE3","title":"Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome","status":"COMPLETED","sponsor":"Anne Comi, MD","startDate":"2017-01","conditions":"Sturge-Weber Syndrome","enrollment":10},{"nctId":"NCT04482712","phase":"PHASE1, PHASE2","title":"Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-04","conditions":"Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure, Sars-CoV2","enrollment":""},{"nctId":"NCT03582878","phase":"PHASE4","title":"Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2004-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":238},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT04736589","phase":"PHASE3","title":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College","startDate":"2021-02-02","conditions":"Breast Cancer","enrollment":270},{"nctId":"NCT03732248","phase":"PHASE1","title":"Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-07-12","conditions":"Alcohol Use Disorder, Alcohol Dependence","enrollment":21},{"nctId":"NCT01197170","phase":"PHASE1","title":"Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09-07","conditions":"Solid Tumors, Advanced Cancer","enrollment":277},{"nctId":"NCT04212702","phase":"","title":"ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-05-22","conditions":"Metastatic Breast Cancer","enrollment":123},{"nctId":"NCT01482156","phase":"PHASE1","title":"Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma","enrollment":46},{"nctId":"NCT01467986","phase":"PHASE2","title":"Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2013-08","conditions":"Neuroblastoma Recurrent","enrollment":130},{"nctId":"NCT02061397","phase":"PHASE1, PHASE2","title":"Safety of Simvastatin in LAM and TSC","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-03","conditions":"Lymphangioleiomyomatosis, Tuberous Sclerosis Complex","enrollment":10},{"nctId":"NCT04409691","phase":"PHASE1","title":"SCMC Trial on KHE With KMP (V.2020)","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2020-07-01","conditions":"Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP)","enrollment":20},{"nctId":"NCT04406870","phase":"PHASE4","title":"Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2020-07","conditions":"Hemangioendothelioma of Liver","enrollment":36},{"nctId":"NCT03618355","phase":"PHASE1","title":"Trial of eRapa in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Rapamycin Holdings, Inc. dba Emtora Biosciences","startDate":"2018-08-28","conditions":"Prostate Cancer","enrollment":15},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT00565773","phase":"PHASE2","title":"Belatacept Post Depletional Repopulation to Facilitate Tolerance","status":"COMPLETED","sponsor":"Allan D Kirk, MD, PhD","startDate":"2007-12","conditions":"Organ Transplantation","enrollment":40},{"nctId":"NCT02376985","phase":"PHASE3","title":"Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2015-03-26","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT00006178","phase":"PHASE2","title":"Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-08","conditions":"Kidney Failure","enrollment":12},{"nctId":"NCT03657420","phase":"PHASE1","title":"Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02077556","phase":"PHASE4","title":"Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Drug Interaction Potentiation","enrollment":14},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT01116232","phase":"PHASE2","title":"Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-08","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":4},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT00311623","phase":"PHASE1, PHASE2","title":"Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-08","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT01713946","phase":"PHASE3","title":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04-29","conditions":"Tuberous Sclerosis Complex-associated Refractory Seizures","enrollment":366},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT02352844","phase":"PHASE2","title":"Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-10-07","conditions":"Solid Malignancy, Solid Tumor","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TORISEL","rapamycin","Rapamune"],"phase":"marketed","status":"active","brandName":"Sirolimus Oral Product","genericName":"Sirolimus Oral Product","companyName":"Shanghai Children's Medical Center","companyId":"shanghai-children-s-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key regulator of cell proliferation and immune cell activation. Used for Organ transplant rejection prophylaxis, Lymphangioleiomyomatosis (LAM), Tuberous sclerosis complex-associated conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}